Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Condition(s):Gastroesophageal Reflux Disease (GERD)Last Updated:April 25, 2022Completed
Hide Studies Not Open or Pending
Condition(s):Gastroesophageal Reflux Disease (GERD)Last Updated:April 25, 2022Completed
Condition(s):Gastroesophageal Reflux DiseaseLast Updated:June 8, 2009Withdrawn
Condition(s):Vesicoureteral RefluxLast Updated:January 5, 2017Completed
Condition(s):Achalasia; Gastroesophageal RefluxLast Updated:July 22, 2022Enrolling by invitation
Condition(s):Gastro-esophageal RefluxLast Updated:December 17, 2020Completed
Condition(s):Gastroesophageal Reflux DiseaseLast Updated:July 28, 2011Completed
Condition(s):Achalasia Cardia; Gastroesophageal RefluxLast Updated:January 31, 2023Completed
Condition(s):Laryngopharyngeal RefluxLast Updated:October 1, 2019Terminated
Condition(s):Gastroesophageal Reflux DiseaseLast Updated:January 18, 2024Active, not recruiting
Condition(s):Gastroesophageal Reflux DiseaseLast Updated:July 24, 2015Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.